Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients
This study is to evaluate long-term safety and efficacy after concomitant administration of ASP1941 and α-glucosidase inhibitor in Japanese patients with type 2 diabetes mellitus.
- Trial name
- NCT01242202
- Testing
- ipragliflozin, alpha glucosidase inhibitor
- Where
- 6 sites in Japan
- Volunteers
- 113 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes Mellitus
FTIH of ECC5004 in Healthy and Diabetic Participants
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC5004 in healthy participants and in patients with Type 2 Diabetes Mellitus
- Trial name
- NCT05654831
- Testing
- ECC5004
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Eccogene
Obesity
A Study on Efficacy and Safety of Topiramate in Maintaining Weight Loss in Obese Patients Following an Intensive, Non-Pharmacologic Weight Loss Program
The purpose of this study is to compare the efficacy and safety of topiramate 96mg and 192mg daily) with placebo in the treatment of obesity following an intensive non-pharmacologic weight loss program.
- Trial name
- NCT00236600
- Testing
- topiramate
- Volunteers
- 561 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus, Type 2
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
This study is a phase 3b, multicentre, randomised, open label, parallel group study. A 4-week run-in period will be followed by a median of 6 years of treatment with study medication in addition to continuation of background…
- Trial name
- RECORD (NCT00379769)
- Testing
- Rosiglitazone, Sulfonylurea, Metformin
- Where
- 446 sites in Australia, Belgium and 23 more
- Volunteers
- 4,447 people
- Sponsor
- GlaxoSmithKline
Hypertension, Diabetic Nephropathy
A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril
The purpose of this study is to evaluate the efficacy of valsartan, benazepril or the combination of both in reduction of microalbuminuria in Type 2 diabetic patients.
- Trial name
- NCT00171119
- Testing
- valsartan
- Where
- Switzerland
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus, Cardiovascular Disease
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
This study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with…
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control
- Trial name
- NCT01042977
- Testing
- Dapagliflozin
- Where
- 135 sites in United States, Argentina and 8 more
- Volunteers
- 964 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin
This is a randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of evogliptin after oral administration in patients with type 2 diabetes who have inadequate glycemic control…
- Trial name
- NCT02946541
- Testing
- evogliptin 5mg
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Dong-A ST Co., Ltd.
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus
The main purpose of this study is to assess the safety and tolerability of multiple subcutaneous injections of HRS9531 in patients with type 2 diabetes mellitus who have suboptimal glycaemic control after conventional lifestyle…
- Trial name
- NCT05516966
- Testing
- HRS9531, Dulaglutide Injection
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656
The purpose of this study is to evaluate the effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656
- Trial name
- NCT01083212
- Testing
- AZD1656, Gemfibrozil
- Where
- 3 sites in Sweden
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)
This study will evaluate whether the addition of Sitagliptin treatment provides a greater decrease in A1C levels compared to placebo in participants with inadequate glycemic control on sulfonylurea and metformin combination…
- Trial name
- NCT01076075
- Testing
- Sitagliptin phosphate, Comparator: pioglitazone, Glimepiride or gliclazide
- Volunteers
- 427 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Kidney Disease, Type 2 Diabetes Mellitus
A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.
- Trial name
- NCT01847092
- Testing
- AZD1722
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Ardelyx
Diabetes, Magnetic Resonance Imaging
Cardiovascular Contrast-enhanced Magnetic Resonance Imaging Using Polysaccharide Superparamagnetic Iron Oxide Injection in Diabetic Patients
This is an open-label, single-center, single-dose study aims to evaluate the effect and safety of polymeric superparamagnetic iron oxide in cardiovascular magnetic resonance imaging for diabetic patients with concomitant chronic…
- Trial name
- NCT06051565
- Testing
- Polysaccharide superparamagnetic iron oxide injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus
To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 187004 following multiple dose administration over 14 days.
- Trial name
- NCT01874483
- Testing
- BI 187004
- Where
- Germany
- Volunteers
- 71 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia
The purpose of the study is to collect information on how Tresiba® works in real world patients. Patients will get Tresiba® as prescribed to them by their study doctor. The study will last for about 6 to 8 months.
- Trial name
- UPDATES (NCT03785522)
- Testing
- Insulin degludec
- Where
- 21 sites in Saudi Arabia
- Volunteers
- 597 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
The purpose of this study is to evaluate the efficacy, safety and tolerability of ISIS-GCGRRx in combination with metformin versus placebo + metformin
- Trial name
- NCT01885260
- Testing
- ISIS-GCGRRx - Dose Level 1, ISIS-GCGRRx - Dose Level 2
- Where
- 24 sites in United States, South Africa
- Volunteers
- 77 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Type 2 Diabetes
Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes
This extension study is designed to evaluate the long-term safety and tolerability of colesevelam hydrochloride (WelChol®) in patients with type 2 diabetes.
- Trial name
- NCT00151762
- Testing
- Colesevelam hydrochloride
- Where
- 64 sites in United States, Mexico and 1 more
- Volunteers
- 780 people
- Sponsor
- Daiichi Sankyo
Malignant Melanoma
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
This study was a mixed phase Ib/II, multi-center, open-label study of tebentafusp (IMCgp100) as a single agent, and in combination with durvalumab and/or tremelimumab, in metastatic cutaneous melanoma.
- Trial name
- NCT02535078
- Testing
- Tebentafusp (IMCgp100)
- Where
- 4 sites in United States
- Sponsor
- Immunocore Ltd
Type 2 Diabetes
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.
- Trial name
- NCT06716424
- Testing
- iGlarLixi (insulin glargine/lixisenatide)
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India
This study is conducted in Asia. The aim of this study is to evaluate long term safety and efficacy in patients with diabetes mellitus in routine clinical practice in India.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT02230618
- Testing
- insulin degludec/insulin aspart
- Where
- 35 sites in India
- Volunteers
- 1,029 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Therapeutic Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of JP-2266 in Patients with Type 2 Diabetes Mellitus
- Trial name
- NCT06144788
- Testing
- SGLT2 inhibitor
- Where
- South Korea
- Volunteers
- 161 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.